Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial

Role of the receptor tyrosine kinase Axl in hepatocellular carcinoma and its clinical relevance

(2019) Zhao-Shan Niu et al.   Future Oncology

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Andrew X Zhu et al.   LANCET ONCOLOGY

Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma

(2019) David J. Pinato et al.   BRITISH JOURNAL OF CANCER

Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).

(2019) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2).

(2019) Josep M Llovet et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

(2018) Andrew X Zhu et al.   LANCET ONCOLOGY

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

(2018) Lorenza Rimassa et al.   LANCET ONCOLOGY

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

(2018) Ghassan K. Abou-Alfa et al.   NEW ENGLAND JOURNAL OF MEDICINE

Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications

(2018) Javier A García-Vilas et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Jordi Bruix et al.   LANCET

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib

(2015) Massimo Iavarone et al.   HEPATOLOGY

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

(2015) Andrew X Zhu et al.   LANCET ONCOLOGY

Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET

(2014) Q. Xiang et al.   CLINICAL CANCER RESEARCH

Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design

(2013) Maria Reig et al.   HEPATOLOGY

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

(2011) F. M. Yakes et al.   MOLECULAR CANCER THERAPEUTICS

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE